Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METAFORE: Bevacizumab for severe hepatic forms of hereditary hemorrhagic telangiectasia
2008-006755-44Phase 2Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), sponsored by Hospices Civils de Lyon. Primary endpoints: Cardiac output reduction and Safety and tolerance of bevacizumab. Started Mar 2009; status: active.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2008-006755-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006755-44.